• Profile
Close

Adjuvant pazopanib vs placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT Trial trial

European Urology Jan 20, 2021

Motzer RJ, Russo P, Haas N, et al. - Researchers designed a randomized, double-blind, placebo-controlled phase 3 study (PROTECT) to assess adjuvant pazopanib in patients with locally advanced renal cell carcinoma (RCC) at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769). No difference in disease-free survival between pazopanib 600 mg and placebo was seen in the results of the primary analysis, so here researchers reported the final overall survival (OS) analysis. There was no variation in disease-free survival between pazopanib 600 mg and placebo. For patients with locally advanced RCC at high risk of relapse following nephrectomy who received adjuvant therapy with pazopanib or placebo, overall survival was comparable. The results support that pazopanib should not be recommended as adjuvant therapy afterresection of locally advanced RCC.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay